drugset
drugset / Trial / NCT04634149

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment

NCT04634149 ↗

Phase 1 Completed 16 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the effect of impaired liver function on the drug levels, safety, and tolerability of BMS-986036 in participants with moderate and severe liver impairment. Results from this study will be used to determine whether dose adjustment is required for patients with decreased liver function.

Timeline

Start
2020-11-23
Primary completion
2022-06-02
Completion
2022-06-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegbelfermin Protein / enzyme biologic — —

Indications

liver disorder